JOINTstat™ – Transforming RA Patient Management

LifeLabs Medical Laboratory Services, the country’s largest provider of community laboratory services, yesterday announced the Canadian launch of JOINTstat™ (14-3-3η), a biomarker blood test that is providing transformational insights into autoimmune joint damage mechanisms and the clinical management of rheumatoid arthritis (RA). Augurex will proudly attend with LifeLabs, the 2015 Canadian Rheumatology Association (CRA) Annual Scientific Meeting, February 4-7, 2015 in Quebec City, where 14-3-3η data in over 800 patients will be presented with leading Canadian and international investigators.

Title/Principle Investigator Date and Time
Elevated 14-3-3η serum protein levels increase RA confirmation in recent-onset polyarthritis patients. Gilles Boire, MD Friday,
Feb. 6, 2015, 8:45 am
Podium Presentation #10
14-3-3η levels predict radiographic progression in recent-onset polyarthritis patients. Gilles Boire, MD Thursday, Feb. 5, 2015, 4:00 – 5:30pm
Poster #77
Independent validation of the 14-3-3η assay: a diagnostic RA marker. Nicola Hughes, PhD Thursday, Feb. 5, 2015, 4:00 – 5:30pm
Poster #111
14-3-3η: a mechanistic biomarker that supports the concept of “uncoupling” of inflammation and joint damage. Dirkjan van Schaardenburg, MD Thursday, Feb. 5, 2015, 4:00 – 5:30pm
Poster #11
Autoantibodies to 14-3-3η are novel biomarkers associated with inflammation and radiographic progression in ankylosing spondylitis. Walter Maksymowych, MD Thursday, Feb. 5, 2015, 4:00 – 5:30pm
Poster #217
LifeLabs will also host a Webinar on February 24, 2015 at 5:30 PM EST, titledIntroducing JOINTstat™: A new Biomechanistic Marker for the Early Diagnosis of Rheumatoid Arthritis presented by Walter Maksymowych, MD  F.R.C.P.(C). This event can be accessed using the following event details.
  1. Meeting ID: 298-901-673
  2. Join the conference call:  1-855-453-6959 ID: 7140585
Peer-reviewed publications describing the mechanistic role of 14-3-3η in joint damage pathogenesis, its applications for early RA diagnosis  and a recent editorial, provide perspectives on the transformational characteristics of this biomarker. For more information regarding Augurex’s emerging JOINTstat™ (14-3-3η) portfolio and corresponding publications please visit